Companies › Pluto
1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PLH-2301 | – | Phase 2 | Sarcopenia in Elderly | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07390552 | PLH-2301 | Phase 2 | Sarcopenia in Elderly | Other | Jun 2027 |
No annotated target.
–
Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical Dendrogenix
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.